300723 一品红
已收盘 10-30 15:00:00
资讯
新帖
简况
一品红前三季度归母净利润同比增长381.19% AR882国内Ⅲ期达到主要临床终点
东方财富网 · 11:40
一品红前三季度归母净利润同比增长381.19% AR882国内Ⅲ期达到主要临床终点
图解一品红三季报：第三季度单季净利润同比下降63.21%
证券之星 · 03:40
图解一品红三季报：第三季度单季净利润同比下降63.21%
一品红前三季度利润分配：拟每10股派息5元
财中社 · 10-29 18:52
一品红前三季度利润分配：拟每10股派息5元
股市必读：一品红（300723）10月21日董秘有最新回复
证券之星 · 10-22
股市必读：一品红（300723）10月21日董秘有最新回复
股市必读：一品红新发布《关于全资子公司获得帕拉米韦注射液注册证书的公告》
证券之星 · 10-19
股市必读：一品红新发布《关于全资子公司获得帕拉米韦注射液注册证书的公告》
一品红（300723）披露全资子公司获得帕拉米韦注射液注册证书公告，10月16日股价上涨0.82%
证券之星 · 10-16
一品红（300723）披露全资子公司获得帕拉米韦注射液注册证书公告，10月16日股价上涨0.82%
一品红：截止至2026年9月30日，公司股东总户数30,828户
证券之星 · 10-16
一品红：截止至2026年9月30日，公司股东总户数30,828户
一品红(300723.SZ)子公司获得帕拉米韦注射液注册证书
智通财经 · 10-16
一品红(300723.SZ)子公司获得帕拉米韦注射液注册证书
一品红（300723）10月13日主力资金净卖出1671.11万元
证券之星 · 10-14
一品红（300723）10月13日主力资金净卖出1671.11万元
股市必读：一品红新发布《关于2024年员工持股计划第二个锁定期届满的提示性公告》
证券之星 · 10-13
股市必读：一品红新发布《关于2024年员工持股计划第二个锁定期届满的提示性公告》
股市必读：一品红新发布《关于全资子公司获得艾曲泊帕乙醇胺干混悬剂注册证书的公告》
证券之星 · 10-12
股市必读：一品红新发布《关于全资子公司获得艾曲泊帕乙醇胺干混悬剂注册证书的公告》
一品红（300723）披露全资子公司获得艾曲泊帕乙醇胺干混悬剂注册证书，10月09日股价上涨1.77%
证券之星 · 10-09
一品红（300723）披露全资子公司获得艾曲泊帕乙醇胺干混悬剂注册证书，10月09日股价上涨1.77%
一品红(300723.SZ)子公司获得艾曲泊帕乙醇胺干混悬剂注册证书
智通财经 · 10-08
一品红(300723.SZ)子公司获得艾曲泊帕乙醇胺干混悬剂注册证书
一品红：创新药APH04935片获美国FDA临床试验批准
格隆汇 · 10-08
一品红：创新药APH04935片获美国FDA临床试验批准
一品红(300723.SZ)子公司创新药APH04935片获得美国FDA临床试验批准
智通财经 · 10-08
一品红(300723.SZ)子公司创新药APH04935片获得美国FDA临床试验批准
一品红（300723）披露全资子公司获得盐酸非索非那定口服混悬液注册证书的公告，9月28日股价下跌2.11%
证券之星 · 09-28
一品红（300723）披露全资子公司获得盐酸非索非那定口服混悬液注册证书的公告，9月28日股价下跌2.11%
一品红（300723）披露全资子公司获得复方聚乙二醇（3350）电解质口服溶液注册证书公告，9月21日股价上涨3.14%
证券之星 · 09-21
一品红（300723）披露全资子公司获得复方聚乙二醇（3350）电解质口服溶液注册证书公告，9月21日股价上涨3.14%
一品红子公司聚乙二醇（3350）电解质口服溶液获国家药监局药品注册证书
美股速递 · 09-20
一品红子公司聚乙二醇（3350）电解质口服溶液获国家药监局药品注册证书
一品红最新公告：全资子公司获复方聚乙二醇电解质口服溶液注册证书
证券之星 · 09-20
一品红最新公告：全资子公司获复方聚乙二醇电解质口服溶液注册证书
一品红痛风创新药Ⅲ期临床达到主要终点 大中华区销售峰值预计达19.5亿元
新浪证券 · 09-11
一品红痛风创新药Ⅲ期临床达到主要终点 大中华区销售峰值预计达19.5亿元
加载更多
公司概况
公司名称：
一品红药业集团股份有限公司
所属行业：
医药制造业
上市日期：
2017-11-16
主营业务：
一品红药业集团股份有限公司的主营业务是药品研发、生产、销售。公司的主要产品是特色儿童药、创新慢病药。
发行价格：
17.05
{"stockData":{"symbol":"300723","market":"SZ","secType":"STK","nameCN":"一品红","latestPrice":27.66,"timestamp":1793343831000,"preClose":28.32,"halted":0,"volume":4506810,"delay":0,"changeRate":-0.0233,"floatShares":421000000,"shares":453000000,"eps":0.3993,"marketStatus":"已收盘","change":-0.66,"latestTime":"10-30 15:00:00","open":28.05,"high":29.08,"low":27.33,"amount":126000000,"amplitude":0.0618,"askPrice":27.66,"askSize":484,"bidPrice":27.65,"bidSize":15,"shortable":0,"etf":0,"ttmEps":0.3993,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1793583000000},"marketStatusCode":5,"adr":0,"adjPreClose":28.32,"symbolType":"stock","openAndCloseTimeList":[[1793323800000,1793331000000],[1793336400000,1793343600000]],"highLimit":31.15,"lowLimit":25.49,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":453184556,"isCdr":false,"pbRate":7.25,"roa":"--","peRate":69.271225,"roe":"24.52%","epsLYR":-0.7478,"committee":-0.848416,"marketValue":12535000000,"turnoverRate":0.0107,"status":1,"floatMarketCap":11636000000},"requestUrl":"/m/hq/s/300723","defaultTab":"news","newsList":[{"id":"2679500263","title":"一品红前三季度归母净利润同比增长381.19% AR882国内Ⅲ期达到主要临床终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2679500263","media":"东方财富网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679500263?lang=zh_cn&edition=full","pubTime":"2026-10-30 11:40","pubTimestamp":1793331600,"startTime":"0","endTime":"0","summary":"10月29日晚间，一品红药业集团股份有限公司（以下简称“一品红”）发布2026年三季度报告。报告显示，该公司前三季度实现营业收入61653.16万元，同比下降24.26%；实现归属于上市公司股东的净利润38265.37万元，同比增加381.19%，实现扭亏为盈；经营活动产生的现金流量净额6201.65万元，同比增加637.87%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"east_money_stock","url":"http://stock.eastmoney.com/news/11215,202610303916092746.html","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.eastmoney.com/news/11215,202610303916092746.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"east_money_stock","symbols":["300723"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679690233","title":"图解一品红三季报：第三季度单季净利润同比下降63.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=2679690233","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679690233?lang=zh_cn&edition=full","pubTime":"2026-10-30 03:40","pubTimestamp":1793302824,"startTime":"0","endTime":"0","summary":"证券之星消息，一品红2026年三季报显示，前三季度公司主营收入6.17亿元，同比下降24.26%；归母净利润3.83亿元，同比上升381.19%；扣非净利润-2.43亿元，同比下降35.67%；其中2026年第三季度，公司单季度主营收入1.25亿元，同比下降45.78%；单季度归母净利润-1.02亿元，同比下降63.21%；单季度扣非净利润-1.12亿元，同比下降57.65%；负债率58.23%，投资收益5.82亿元，财务费用3839.62万元，毛利率50.95%。财报数据概要请见下图:本文数据来源于一品红2026年三季报，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026103000005870.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300723"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679540437","title":"一品红前三季度利润分配：拟每10股派息5元","url":"https://stock-news.laohu8.com/highlight/detail?id=2679540437","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679540437?lang=zh_cn&edition=full","pubTime":"2026-10-29 18:52","pubTimestamp":1793271120,"startTime":"0","endTime":"0","summary":"10月29日，一品红（300723）发布公告，公司拟向全体股东每10股派发现金红利5元（含税），预计总派发金额为2.25亿元。2026年前三季度，一品红实现收入6.17亿元，归母净利润3.83亿元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-10-29/doc-iniwwyat8756737.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["300723","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677960420","title":"股市必读：一品红（300723）10月21日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2677960420","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677960420?lang=zh_cn&edition=full","pubTime":"2026-10-22 04:04","pubTimestamp":1792613055,"startTime":"0","endTime":"0","summary":"截至2026年10月21日收盘，一品红报收于30.86元，下跌0.71%，换手率0.66%，成交量2.77万手，成交额8642.09万元。公司将严格按照相关法律法规要求履行信息披露义务。当日关注点交易信息汇总：10月21日主力资金净流入12.13万元，占总成交额0.14%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102200003544.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300723"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676573033","title":"股市必读：一品红新发布《关于全资子公司获得帕拉米韦注射液注册证书的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2676573033","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676573033?lang=zh_cn&edition=full","pubTime":"2026-10-19 04:17","pubTimestamp":1792354629,"startTime":"0","endTime":"0","summary":"公司公告汇总：全资子公司获帕拉米韦注射液《药品注册证书》，该药已纳入国家医保乙类目录，2025年公立医院销售规模约80,860万元。公司公告汇总关于全资子公司获得帕拉米韦注射液注册证书的公告一品红药业集团股份有限公司全资子公司广州一品红制药有限公司近日收到国家药品监督管理局核准签发的帕拉米韦注射液《药品注册证书》。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101900001344.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300723","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675598961","title":"一品红（300723）披露全资子公司获得帕拉米韦注射液注册证书公告，10月16日股价上涨0.82%","url":"https://stock-news.laohu8.com/highlight/detail?id=2675598961","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675598961?lang=zh_cn&edition=full","pubTime":"2026-10-16 17:31","pubTimestamp":1792143085,"startTime":"0","endTime":"0","summary":"截至2026年10月16日收盘，一品红报收于30.86元，较前一交易日上涨0.82%，最新总市值为139.39亿元。一品红药业集团股份有限公司于2026年10月16日披露公告，其全资子公司广州一品红制药有限公司近日收到国家药品监督管理局核准签发的帕拉米韦注射液《药品注册证书》。药品有效期24个月，批准文号有效期至2031年10月12日。帕拉米韦注射液已纳入国家医保乙类目录，2025年在中国城市和县级公立医院销售规模约80,860万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101600029948.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300723"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675562281","title":"一品红：截止至2026年9月30日，公司股东总户数30,828户","url":"https://stock-news.laohu8.com/highlight/detail?id=2675562281","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675562281?lang=zh_cn&edition=full","pubTime":"2026-10-16 16:30","pubTimestamp":1792139431,"startTime":"0","endTime":"0","summary":"证券之星消息，一品红(300723)10月16日在投资者关系平台上答复投资者关心的问题。投资者提问：你好，最新的股东人数一品红回复：尊敬的投资者您好，感谢您对公司的关注。截止至2026年9月30日，公司股东总户数30,828户。祝您投资愉快。本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101600027854.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300723"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675550223","title":"一品红(300723.SZ)子公司获得帕拉米韦注射液注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2675550223","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675550223?lang=zh_cn&edition=full","pubTime":"2026-10-16 11:48","pubTimestamp":1792122491,"startTime":"0","endTime":"0","summary":"智通财经APP讯，一品红(300723.SZ)发布公告，公司全资子公司广州一品红制药有限公司于近日收到国家药品监督管理局核准签发的关于帕拉米韦注射液的《药品注册证书》。该药品用于治疗甲型或乙型流行性感冒。目前，帕拉米韦注射液已被纳入国家医保乙类目录。公司获批的帕拉米韦注射液是以化学药品3类申报注册，视同通过一致性评价。根据米内网数据，2025年帕拉米韦在中国城市和县级公立医院的销售规模约为8.09亿元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1508164.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","300723"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675399529","title":"一品红（300723）10月13日主力资金净卖出1671.11万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2675399529","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675399529?lang=zh_cn&edition=full","pubTime":"2026-10-14 09:12","pubTimestamp":1791940367,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年10月13日收盘，一品红报收于31.43元，下跌3.05%，换手率0.97%，成交量4.05万手，成交额1.27亿元。10月13日的资金流向数据方面，主力资金净流出1671.11万元，占总成交额13.13%，游资资金净流入109.02万元，占总成交额0.86%，散户资金净流入1562.09万元，占总成交额12.27%。融券方面，融券卖出3600.0股，融券偿还400.0股，融券余量10.4万股，融券余额326.95万元。一品红主营业务：药品的研发、生产和销售。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101400008306.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300723","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675804851","title":"股市必读：一品红新发布《关于2024年员工持股计划第二个锁定期届满的提示性公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2675804851","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675804851?lang=zh_cn&edition=full","pubTime":"2026-10-13 01:24","pubTimestamp":1791825854,"startTime":"0","endTime":"0","summary":"当日关注点交易信息汇总：10月12日主力资金净流出901.45万元，占总成交额6.53%； 公司公告汇总：一品红2024年员工持股计划第二个锁定期于2026年10月10日届满，对应股票5,116,105股，第二期解锁条件已达成。公司公告汇总关于2024年员工持股计划第二个锁定期届满的提示性公告一品红药业集团股份有限公司2024年员工持股计划第二个锁定期于2026年10月10日届满。员工持股计划存续期为48个月，存续期内遵守信息敏感期禁止交易规定。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101300001684.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300723","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674846604","title":"股市必读：一品红新发布《关于全资子公司获得艾曲泊帕乙醇胺干混悬剂注册证书的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2674846604","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674846604?lang=zh_cn&edition=full","pubTime":"2026-10-12 03:42","pubTimestamp":1791747733,"startTime":"0","endTime":"0","summary":"公司公告汇总：全资子公司获艾曲泊帕乙醇胺干混悬剂《药品注册证书》，注册分类为化学药品3类，视同通过一致性评价，适应症为慢性免疫性血小板减少症和重型再生障碍性贫血。公司公告汇总关于全资子公司获得艾曲泊帕乙醇胺干混悬剂注册证书的公告一品红药业集团股份有限公司全资子公司广州市联瑞制药有限公司近日收到国家药品监督管理局核准签发的艾曲泊帕乙醇胺干混悬剂《药品注册证书》。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101200001187.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300723","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674858165","title":"一品红（300723）披露全资子公司获得艾曲泊帕乙醇胺干混悬剂注册证书，10月09日股价上涨1.77%","url":"https://stock-news.laohu8.com/highlight/detail?id=2674858165","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674858165?lang=zh_cn&edition=full","pubTime":"2026-10-09 17:56","pubTimestamp":1791539789,"startTime":"0","endTime":"0","summary":"截至2026年10月9日收盘，一品红报收于33.42元，较前一交易日上涨1.77%，最新总市值为150.96亿元。一品红药业集团股份有限公司于2026年10月9日发布公告称，其全资子公司广州市联瑞制药有限公司近日收到国家药品监督管理局核准签发的艾曲泊帕乙醇胺干混悬剂《药品注册证书》。药品有效期24个月，批准文号有效期至2031年9月28日。上市许可持有人和生产企业均为广州市联瑞制药有限公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026100900028443.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300723"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673024214","title":"一品红(300723.SZ)子公司获得艾曲泊帕乙醇胺干混悬剂注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2673024214","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673024214?lang=zh_cn&edition=full","pubTime":"2026-10-08 16:03","pubTimestamp":1791446586,"startTime":"0","endTime":"0","summary":"智通财经APP讯，一品红(300723.SZ)发布公告，公司全资子公司广州市联瑞制药有限公司于近日收到国家药品监督管理局核准签发的关于艾曲泊帕乙醇胺干混悬剂的《药品注册证书》。此次公司获得艾曲泊帕乙醇胺干混悬剂注册证书，标志着公司具备了在国内市场销售该规格药品的资格，将进一步丰富公司产品管线和产品品类，增强了公司的核心竞争力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1504573.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","300723"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673804032","title":"一品红：创新药APH04935片获美国FDA临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2673804032","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673804032?lang=zh_cn&edition=full","pubTime":"2026-10-08 12:04","pubTimestamp":1791432299,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["159992","300723","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673477770","title":"一品红(300723.SZ)子公司创新药APH04935片获得美国FDA临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2673477770","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673477770?lang=zh_cn&edition=full","pubTime":"2026-10-08 11:52","pubTimestamp":1791431539,"startTime":"0","endTime":"0","summary":"智通财经APP讯，一品红(300723.SZ)发布公告，近日，公司全资子公司广州一品红制药有限公司(简称“一品红制药”)收到美国食品药品监督管理局(FDA)下发的关于同意公司子公司自主研发的创新药物APH04935片临床试验的函。APH04935 片是由公司自主研发的一种高活性、高选择性的小分子GLP-1R(全称：Glucagon-like Peptide-1 Receptor，中文译为：胰高血糖素样肽-1 受体)激动剂，目标成为一款一天给药一次的口服小分子 GLP-1R 激动剂，拟用于控制体重及长期减重管理。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1504498.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","06978","IBBQ","300723","LNGR","MEDX","BBC","159992","BK0239","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670222253","title":"一品红（300723）披露全资子公司获得盐酸非索非那定口服混悬液注册证书的公告，9月28日股价下跌2.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2670222253","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670222253?lang=zh_cn&edition=full","pubTime":"2026-09-28 22:14","pubTimestamp":1790604869,"startTime":"0","endTime":"0","summary":"截至2026年9月28日收盘，一品红报收于32.5元，较前一交易日下跌2.11%，最新总市值为146.8亿元。该股当日开盘33.34元，最高33.51元，最低32.26元，成交额达1.07亿元，换手率为0.79%。近日，一品红药业集团股份有限公司全资子公司广州一品红制药有限公司收到国家药品监督管理局核准签发的盐酸非索非那定口服混悬液《药品注册证书》。药品批准文号为国药准字H20266079，有效期至2031年9月21日。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092800034728.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300723"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669154941","title":"一品红（300723）披露全资子公司获得复方聚乙二醇（3350）电解质口服溶液注册证书公告，9月21日股价上涨3.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2669154941","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669154941?lang=zh_cn&edition=full","pubTime":"2026-09-21 17:36","pubTimestamp":1789983374,"startTime":"0","endTime":"0","summary":"截至2026年9月21日收盘，一品红报收于34.83元，较前一交易日上涨3.14%，最新总市值为157.32亿元。该股当日开盘34.02元，最高35.21元，最低34.02元，成交额达2.58亿元，换手率为1.77%。一品红药业集团股份有限公司于近日披露公告，其全资子公司广州一品红制药有限公司收到国家药品监督管理局核准签发的复方聚乙二醇电解质口服溶液《药品注册证书》。药品批准文号有效期至2031年9月14日。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092100022370.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300723"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195679883","title":"一品红子公司聚乙二醇（3350）电解质口服溶液获国家药监局药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=1195679883","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1195679883?lang=zh_cn&edition=full","pubTime":"2026-09-20 16:54","pubTimestamp":1789894451,"startTime":"0","endTime":"0","summary":"一品红制药集团宣布，其子公司研发的聚乙二醇（3350）电解质口服溶液，已成功取得国家药品监督管理局（NMPA）颁发的药品注册证书。这一重要进展，标志着该产品在合规性与安全性方面获得了权威认可，也为公司进一步拓展市场奠定了坚实基础。据悉，此款口服溶液主要用于肠道清洁准备，其获批将进一步丰富一品红在消化系统用药领域的产品管线，增强其在相关治疗领域的综合竞争力。公司表示，后续将积极推动该产品的生产与上市工作，以满足临床需求。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["300723","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668183096","title":"一品红最新公告：全资子公司获复方聚乙二醇电解质口服溶液注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2668183096","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668183096?lang=zh_cn&edition=full","pubTime":"2026-09-20 16:20","pubTimestamp":1789892403,"startTime":"0","endTime":"0","summary":"一品红(300723.SZ)公告称，公司全资子公司广州一品红制药近日收到国家药监局核准签发的复方聚乙二醇(3350)电解质口服溶液《药品注册证书》，该药品注册分类为化学药品3类，视同通过一致性评价，适应症为治疗慢性便秘、粪便嵌塞。据米内网数据，2025年聚乙二醇在中国城市和县级公立医院销售规模约2.21亿元。此次获批标志着公司具备在国内市场销售该药品资格，将进一步丰富产品管线，增强慢病药竞争力。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092000004138.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300723","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666544603","title":"一品红痛风创新药Ⅲ期临床达到主要终点 大中华区销售峰值预计达19.5亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2666544603","media":"新浪证券","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666544603?lang=zh_cn&edition=full","pubTime":"2026-09-11 15:34","pubTimestamp":1789112040,"startTime":"0","endTime":"0","summary":"近日，一品红自愿披露关于痛风创新药AR882治疗痛风伴高尿酸血症患者Ⅲ期临床研究达到主要终点的公告。商业化权益方面，AR882为一品红自主研发的1类创新药，在大中华区拥有完整的开发、生产与商业化权益，且一品红具备成熟的自有慢病药商业化团队，无需对外支付销售分成。结合0.70的临床成功概率，最终AR882大中华区痛风适应症管线的风险调整净现值约为5.5亿元。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/observe/2026-09-11/doc-inirmvzz2155509.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["06978","159992","BK1161","BK1574","MEDX","LNGR","BK0239","300723","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1793359137099,"stockEarnings":[{"period":"1week","weight":-0.0413},{"period":"1month","weight":-0.1313},{"period":"3month","weight":-0.1977},{"period":"6month","weight":-0.3168},{"period":"1year","weight":-0.4687},{"period":"ytd","weight":-0.1559}],"compareEarnings":[{"period":"1week","weight":-0.0018},{"period":"1month","weight":-0.0467},{"period":"3month","weight":-0.0472},{"period":"6month","weight":-0.112},{"period":"1year","weight":-0.0909},{"period":"ytd","weight":-0.08}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"一品红药业集团股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"30828人(较上一季度减少0.76%)","perCapita":"13646股","listingDate":"2017-11-16","address":"广东省广州市黄埔区广州国际生物岛寰宇一路27号云润大厦17层","registeredCapital":"45318万元","survey":" 一品红药业集团股份有限公司的主营业务是药品研发、生产、销售。公司的主要产品是特色儿童药、创新慢病药。","listedPrice":17.05},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"一品红(300723)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供一品红(300723)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"一品红,300723,一品红股票,一品红股票老虎,一品红股票老虎国际,一品红行情,一品红股票行情,一品红股价,一品红股市,一品红股票价格,一品红股票交易,一品红股票购买,一品红股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"一品红(300723)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供一品红(300723)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}